Literature DB >> 20554710

Evidence of cognitive and neurophysiological impairment in patients with untreated naive acromegaly.

José Leon-Carrion1, Juan Francisco Martin-Rodriguez, Ainara Madrazo-Atutxa, Alfonso Soto-Moreno, Eva Venegas-Moreno, Elena Torres-Vela, Pedro Benito-López, Maria Angeles Gálvez, Francisco J Tinahones, Alfonso Leal-Cerro.   

Abstract

CONTEXT: Recent studies have suggested that long-term exposure to high levels of GH and IGF-I affect brain and cognitive functions. However, very few human studies have challenged this hypothesis.
OBJECTIVE: The aim of this study is to explore whether GH/IGF-I excess in naive patients with acromegaly alters cognitive functions, particularly memory, and whether these alterations are accompanied by neurophysiological correlates.
DESIGN: We conducted a comprehensive neuropsychological and neurophysiological exam on 16 naive acromegaly patients and 16 strictly matched healthy controls. Comparative analyses were carried out on major neurocognitive domains (executive functions, visual/verbal memory, attention, visuoconstructive abilities, and verbal fluency) and on quantitative electroencephalogram and low-resolution brain electromagnetic tomography sources. Results were correlated with GH and IGF-I hormone concentrations.
RESULTS: Short- and long-term memory were the most severely impaired cognitive functions. Moreover, memory performance correlated negatively with GH and IGF-I concentrations. No association was detected between depression and memory impairment, and only a marginal association was found with quality of life. Finally, acromegaly patients showed power attenuation in fast frequency electroencephalogram bands, as well as decreased activity in prefrontal and middle temporal cortices, that was associated to cognitive performance.
CONCLUSIONS: Results provide evidence of cognitive and neurophysiological impairment, characterized by moderate-to-severe memory impairment and decreased neural activity in specific brain areas. High levels of GH and IGF-I in acromegaly patients could be the basis for these findings.

Entities:  

Mesh:

Year:  2010        PMID: 20554710     DOI: 10.1210/jc.2010-0394

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

1.  Cognitive function in acromegaly: description and brain volumetric correlates.

Authors:  Caroline Sievers; P G Sämann; H Pfister; C Dimopoulou; M Czisch; J Roemmler; J Schopohl; G K Stalla; J Zihl
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

2.  Evaluation of depressive mood and cognitive functions in patients with acromegaly under somatostatin analogue therapy.

Authors:  H Alibas; K Uluc; P Kahraman Koytak; M M Uygur; N Tuncer; T Tanridag; D Gogas Yavuz
Journal:  J Endocrinol Invest       Date:  2017-06-28       Impact factor: 4.256

3.  Perception of health and cognitive dysfunction in acromegaly patients.

Authors:  Iris Crespo; Susan M Webb
Journal:  Endocrine       Date:  2014-03-25       Impact factor: 3.633

4.  Neurocognitive long-term impact of two-field conventional radiotherapy in adult patients with operated pituitary adenomas.

Authors:  Beatriz Lecumberri; Javier Estrada; José García-Uría; Isabel Millán; Luis Felipe Pallardo; Luis Caballero; Tomás Lucas
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

5.  Paternal deprivation prior to adolescence and vulnerability to pituitary adenomas.

Authors:  L G Sobrinho; J S Duarte; I Paiva; L Gomes; V Vicente; P Aguiar
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

6.  Evidence of dysexecutive syndrome in patients with acromegaly.

Authors:  Shaobo Shan; Lingling Fang; Jia Huang; Raymond C K Chan; Guijun Jia; Weiqing Wan
Journal:  Pituitary       Date:  2017-12       Impact factor: 4.107

7.  Cognitive response to estradiol in postmenopausal women is modified by high cortisol.

Authors:  Laura D Baker; Sanjay Asthana; Brenna A Cholerton; Charles W Wilkinson; Stephen R Plymate; Pattie S Green; George R Merriam; Mark A Fishel; G Stennis Watson; Monique M Cherrier; Monica L Kletke; Pankaj D Mehta; Suzanne Craft
Journal:  Neurobiol Aging       Date:  2011-08-19       Impact factor: 4.673

8.  Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study.

Authors:  Chris G Yedinak; Maria Fleseriu
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

9.  Psychological profile and quality of life in patients with acromegaly in Greece. Is there any difference with other chronic diseases?

Authors:  Panagiotis Anagnostis; Zoe A Efstathiadou; Maria Charizopoulou; Despina Selalmatzidou; Eleni Karathanasi; Maria Poulasouchidou; Marina Kita
Journal:  Endocrine       Date:  2014-02-08       Impact factor: 3.633

10.  General health status and intelligence scores of children of mothers with acromegaly do not differ from those of healthy mothers.

Authors:  Ozlem Haliloglu; Burak Dogangun; Bahar Ozcabi; Hanife Ugur Kural; Fatma Ela Keskin; Hande Mefkure Ozkaya; Fatma Colkesen Pamukcu; Elif Bektas; Burc Cagri Poyraz; Hakan Buber; Olcay Evliyaoglu; Pinar Kadioglu
Journal:  Pituitary       Date:  2016-08       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.